ImmunityBio's Anktiva Sales Skyrocket 700%: What It Means for Biotech Investors

What's driving ImmunityBio's stock to soar in 2026? Investors and biotech enthusiasts alike are buzzing with curiosity. Let's dig into the numbers and see what's fueling this remarkable rise.

Impressive Growth by the Numbers

ImmunityBio, a company at the forefront of cancer immunotherapy, has reported a 700% increase in sales for its leading product, Anktiva, in 2025. As of the fourth quarter, Anktiva not only contributed significantly to the company's revenue but also exhibited a 20% quarter-over-quarter growth. Despite earnings per share still being in negative territory at $0.06, it's clear the company is on an upward trajectory, marking its third consecutive quarter of profitability improvement.

This surge hasn't gone unnoticed by the market. ImmunityBio's stock has quintupled this year alone. Yes, you read that right, quintupled. So, what's the story behind these numbers, and what does it mean for investors?

The Bigger Picture

The success of Anktiva and the rise in ImmunityBio's stock price are more than just statistical anomalies. They highlight a significant shift in the approach to cancer treatment. Anktiva, designed to stimulate natural killer cells, cytotoxic T cells, and memory T cells, is tackling cancers and diseases that previously seemed insurmountable.

Initially focusing on bladder cancer cases that didn't respond to the Bacille Calmette-Guérin (BCG) vaccine, ImmunityBio is now expanding its reach. This isn't just about one product. it's about changing the cancer treatment space. And while we're talking about ImmunityBio's U.S.-centric sales, the potential for global expansion can't be ignored.

What Insiders Are Saying

Industry insiders are keenly watching ImmunityBio's strategy. According to market analysts, the rapid adoption of Anktiva signifies a turning point in immunotherapy's acceptance among oncologists and patients. This could very well be a harbinger of broader acceptance and adoption of similar therapies.

But it's not all rosy. Skeptics point to the ongoing financial losses as a concern. They argue that until ImmunityBio turns a profit, there's a risk of volatility. Yet, those who stay through the ups and downs of the biotech sector know that patience often pays off. Will ImmunityBio's next quarterly earnings tell a different story?

What’s Next for ImmunityBio?

The path forward for ImmunityBio is filled with both opportunities and challenges. Investors should keep an eye on the company's global expansion strategies and any new clinical trials that might broaden Anktiva's application. The growing acceptance and application of immunotherapy are encouraging, but the market is also volatile.

Upcoming milestones include potential regulatory approvals for new indications and further international market penetration. These could act as significant catalysts for ImmunityBio's continued growth. In an industry where change is the only constant, how will ImmunityBio adapt and innovate?

For now, the company appears to be on a promising trajectory, but the stakes are high. Investors are left with a key question: Are they willing to bet on ImmunityBio's continued evolution, or will they wait to see if profitability solidifies its long-term viability?